Membranous NephropathyPhase 2REBOOTNCT03949855
Belimumab With Rituximab for Primary Membranous Nephropathy
A Phase 2 study testing Belimumab and Rituximab in people with Membranous Nephropathy and Nephrotic Syndrome, run by National Institute of Allergy and Infectious Diseases (NIAID) at 20 sites in United States.
Trial summary
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Membranous Nephropathy, Nephrotic Syndrome
- What is being tested?
- Belimumab and Rituximab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 58 participants
- Where
- 20 sitesUnited States
- Study dates
- 6 Mar 2020to 1 Mar 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Subjects must meet all of the following criteria to be eligible for this study-
- Age 18 to 75 years inclusive
- Diagnosis of one of the following:
- Primary MN confirmed by a kidney biopsy within the past 5 years
- Primary MN that is relapsing following a CR (Section 3.3.1) or PR (Section 3.3.2), confirmed by a kidney biopsy within the past 7 years
- Nephrotic syndrome with eGFR > 60 mL/min/1.73m2 and no history of immunosuppressant treatment (e.g. glucocorticoids, cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting agent) for nephrotic syndrome, and without evidence of a secondary cause of nephrotic syndrome
Show all 15Show fewer
- Nephrotic syndrome and a contraindication to kidney biopsy (e.g., anticoagulation, solitary kidney, body habitus that increases the risk of biopsy, or other contraindication in the opinion of the investigator), and without evidence of a secondary cause of nephrotic syndrome
- Serum anti-PLA2R positive
- eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade
- Proteinuria:
- ≥ 4 and < 8 g/day that has persisted for at least the previous 3 months while on maximally tolerated RAS blockade. Documentation of persistent proteinuria may be from a 24-hour collection or calculated from a spot urine collection. Or,
- ≥ 8 g/day while on maximally tolerated RAS blockade
- Blood pressure while on maximally tolerated RAS blockade:
- Systolic blood pressure ≤ 140 mmHg
- Diastolic blood pressure ≤ 90 mmHg
Who cannot join
- Subjects meeting any of the following criteria will not be eligible for this study-
- Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation
- Rituximab use within the previous 12 months
- Rituximab use > 12 months ago:
- With an undetectable CD19 B cell count, or
- Did not result in a CR (Section 3.3.1) or PR (Section 3.3.2) with rituximab treatment alone (e.g., without other immunosuppressive or immunomodulatory therapy)
Show all 39Show fewer
- Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)
- Cyclophosphamide use within the past 3 months
- Use of other immunosuppressive medications such as cyclosporine or tacrolimus within the past 30 days
- Use of systemic corticosteroids within the past 30 days
- Use of any biologic investigational agent (defined as any drug not approved for sale in the country it is used) in the previous 12 months
- Use of any non-biologic investigational agent in the past 30 days (or 5 half-lives, whichever is greater)
- Poorly controlled diabetes mellitus defined as hemoglobin A1c (HbA1c) ≥ 9.0%
- Patients with diabetic glomerulopathy on renal biopsy that is:
- Greater than Class I diabetic glomerulopathy, or
- Class I diabetic glomerulopathy with a history of poor diabetic control (e.g., HbA1c ≥ 9.0%) since time of biopsy
- Unstable kidney function defined as > 20% decrease in eGFR during the previous 3 months due to primary MN, as determined by the site investigator in consultation with the protocol chair
- Decrease in proteinuria by 50% or more during the previous 12 months
- WBC count < 3.0 x 103/μl
- Absolute neutrophil count < 1.5 x 103/μl
- Moderately severe anemia (hemoglobin < 9 g/dL)
- History of primary immunodeficiency
- Serum IgA < 10 mg/dL
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2x the upper limit of normal (ULN)
- Positive HIV serology
- Positive HCV serology, unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 24 weeks after cessation of therapy)
- Evidence of current or prior infection with hepatitis B, as indicated by positive HBsAg or positive HBcAb
- Positive QuantiFERON - TB Gold test results. PPD tuberculin test may be substituted for QuantiFERON - TB Gold test
- History of lung disease with FVC < 70% predicted, DLCO < 70% predicted, or requiring supplemental oxygen
- History of malignant neoplasm within the last 5 years except for basal cell or squamous cell carcinoma of the skin treated with local resection only or carcinoma in situ of the uterine cervix treated locally and with no evidence of metastatic disease for 3 years
- Absence of individualized, age-appropriate cancer screening
- Women of child-bearing potential who are pregnant, nursing, or unwilling to be sexually inactive or use FDA-approved contraception until week 104
- Acute or chronic infection, including current use of suppressive therapy for chronic infection, hospitalization for treatment of infection in the past 60 days, or parenteral anti-microbial (including anti-bacterial, anti-viral, or anti-fungal agents) use in the past 60 days for infection
- History of an anaphylactic reaction or known sensitivity or intolerance to parenteral administration of contrast agents, human or murine proteins, or monoclonal antibodies, including rituximab or belimumab
- Evidence of serious suicide risk including any history of suicidal behavior in the last 6 months and/or any suicidal ideation in the last 2 months, or who in the investigator's judgment, poses a significant suicide risk
- Evidence of current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or dependence in the past 12 months
- Vaccination with a live vaccine within the past 30 days
- Other diseases or conditions or other clinically significant abnormal laboratory value which in the opinion of the investigator would put the patient at risk or confound the results of the study
- Inability to comply with study and follow-up procedures
Trial locations and contacts
20 sites in 1 country. Contact the study team or a site near you to ask about taking part.
20 sites in 1 country
United States20 sites, 20 recruiting
- Recruiting
University of Michigan
Ann Arbor, Michigan, 48104
Marie Grutt, 734-232-9358, mfrb@med.umich.edu
Andrea Oliverio
- Recruiting
University of Colorado
Aurora, Colorado, 80045
Lizzy Kickery, 303-724-7790, Lizzy.kickery@cuanschutz.edu
Amber Podoll, MD
- Recruiting
Johns Hopkins
Baltimore, Maryland, 21287
Kristin Lyman, (734) 276-1248, klyman1@jh.edu
Duvuru Geetha
- Recruiting
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Lilian V. Howard, CRNP, 301-594-0298, howardlv@mail.nih.gov
Meryl A. Waldman
- Recruiting
University of Alabama at Birmingham School of Medicine: Division of Nephrology
Birmingham, Alabama, 35294
Maria El Hachem, 205-975-0549, mehachem@uabmc.edu
Dana Rizk
- Recruiting
University of North Carolina School of Medicine: Division of Nephrology and Hypertension, Kidney Center
Chapel Hill, North Carolina, 27599-
Anne Froment, 919-445-2622, anne_froment@med.unc.edu
Vimal K. Derebail
- Recruiting
Cleveland Clinic
Cleveland, Ohio, 44195
Sandra Hodnick, 216-444-0124, hodnics@ccf.org
John Sedor
- Recruiting
Ohio State University Wexner Medical Center: Division of Nephrology
Columbus, Ohio, 43210
Laci Roberts, 614-685-5323, laci.roberts@osumc.edu
Isabelle Ayoub
- Recruiting
Mayo Clinic Jacksonville: Department of Nephrology and Hypertension
Jacksonville, Florida, 32224
Tia Wilkes, 904-953-3636, wilkes.quantia@mayo.edu
Nabeel Aslam
- Recruiting
University of Arkansas
Little Rock, Arkansas, 72205
Gail Runnells, 501-526-7956, RunnellsGailAnn@uams.edu
Srilakshmi Ravula
- Recruiting
University of Miami Miller School of Medicine, Div of Nephrology
Miami, Florida, 33136
Carlos D Bidot, 305-243-8793, cbidot2@med.miami.edu
Jair Munoz Mendoza
- Recruiting
University of Minnesota Health Clinical Research Unit
Minneapolis, Minnesota, 55455
Brady Wallner, 612-626-3415, walln080@umn.edu
Patrick H. Nachman
- Recruiting
Columbia University Medical Center: Division of Nephrology
New York, New York, 10032
Anup Pradhan, 212-305-5037, arp2209@cumc.columbia.edu
Andrew S. Bomback
- Recruiting
University of Nebraska
Omaha, Nebraska, 68198
Tammy Jones, RN, 402-559-4335, tamjones@unmc.edu
Prasanth Ravipati
- Recruiting
University of Pennsylvania: Department of Medicine: Renal-Electrolyte and Hypertension Division
Philadelphia, Pennsylvania, 19104
Krishna Kallem, MD, MPH, 484-358-0315, Krishna.Kallem@pennmedicine.upenn.edu
Gaia Coppock
- Recruiting
University of California San Francisco
San Francisco, California, 94146
Juan Espinoza, 415-502-3618, Juan.Espinoza@ucsf.edu
Raymond Hsu
- Recruiting
Providence Medical Research Center, Providence Health Care: Nephrology
Spokane, Washington, 99204
Nicole Maser, MSH, RN, 509-474-5315, nicole.maser@providence.org
Katherine R. Tuttle
- Recruiting
Washington University in St. Louis
St Louis, Missouri, 63110
Emily Green, 314-273-0339, green.e@wustl.edu
Tinting Li
- Recruiting
Stanford University School of Medicine: Division of Nephrology
Stanford, California, 94305
Brittany Yeung, (650) 498-3116, yeungb@stanford.edu
Elizabeth Chen, echen15@stanford.edu
- Recruiting
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center:Division of Nephrology and Hypertension
Torrance, California, 90502
Janine LaPage, 310-222-4104, jlapage@lundquist.org
Sharon G. Adler
About this study
Official title: Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.
Background:
Read more
Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.
Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.
Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.
In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.
Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
Read the detailed description
This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy (MN), ages 18-75 inclusive. The study will be conducted at multiple sites in the United States and Canada.
Part A: Open-label Phase
Part A is an open-label, PK study to compare belimumab exposure between participants who have "low" proteinuria (≥ 4 to < 8 g/day) and "high" proteinuria (≥ 8 g/day) at Visit -1.
Initially Part A planned to enroll 20 individuals with primary MN: 10 individuals with low proteinuria and 10 individuals with high proteinuria. All Part A participants received 200 mg subcutaneous belimumab weekly, the initially approved dose of belimumab in SLE, for 52 doses (weeks 0-51). Trough serum belimumab levels would be obtained weekly following the first 4 doses of belimumab. All participants would receive rituximab 1000 mg IV at weeks 4 and 6, and are followed after the 52 week treatment period on no study medication until week 156.
Belimumab trough levels were to be analyzed after all 20 participants received the first 4 doses to compare the belimumab exposure between the low and high proteinuria groups. If the belimumab exposure was not comparable between the high and low proteinuria groups, the belimumab dose would be doubled to 400 mg/weekly for participants with high proteinuria in Part B. Dose determination for participants with high proteinuria in Part B would be made by an adjudication committee comprised of the Protocol Chair, NIAID Medical Monitor, ITN Clinical Trial Physician, and Rho Scientist, in consultation with the belimumab PK expert at GSK.
Due in part to the observed imbalance in enrollment between the high and low proteinuria groups, an ad hoc PK analysis was conducted. The serum belimumab trough levels of the first 12 participants (8 with high proteinuria and 4 with low proteinuria) who received the first 4 belimumab doses were analyzed to compare belimumab exposure between the low and high proteinuria groups.
The results of the PK analysis were reviewed by the adjudication committee, who determined that the results did not support doubling the dose of belimumab in individuals with high proteinuria nor did it identify a new proteinuria threshold that warranted an increased belimumab dose. The belimumab PK expert at GSK concurred. Thus, enrollment into Part A has been suspended, and all participants in Part B are to receive the same dose of belimumab. All participants currently enrolled in Part A continue to receive belimumab and rituximab as previously planned and are undergoing the safety assessments as presented in Appendix A.
All enrolled participants in Part A will be followed until week 156 and will be assessed for the same study endpoints as participants in Part B.
Part B: Randomized Phase
Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN to assess the effectiveness of belimumab and rituximab at treating primary MN. Part B is commencing after the completion of the ad hoc PK analysis, which did not support increasing the belimumab dose in participants with high proteinuria.
A total of 58 participants will be randomized into two treatment arms.
Randomization will be stratified by low (≥ 4 to < 8 g/day) and high proteinuria (≥ 8 g/day). Eleven participants who entered Part B prior to protocol version 7.0 were randomized at a 1:1 ratio; 47 participants entering at or after protocol version 7.0 will be randomized at a 3:1 ratio. A total of 41 participants are projected to be enrolled in the belimumab and rituximab arm and 17 participants in the belimumab placebo and rituximab arm. The effectiveness of belimumab with rituximab will be evaluated using a hybrid control arm that combines participants who receive belimumab placebo and rituximab in this study and the subgroup of subjects with primary MN in the MENTOR trial who were anti-PLA2R positive at baseline and received rituximab alone. The randomized arms will also be used to evaluate the safety of adding belimumab to rituximab in primary MN and to support mechanistic studies.
Participants randomized to the belimumab and rituximab arm will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. This dosing regimen is based on the recommended dosing of subcutaneous belimumab for lupus nephritis. Participants randomized to the belimumab placebo and rituximab arm will receive subcutaneous belimumab placebo according to the same dose and schedule.
Participants in both arms will receive rituximab 1000 mg IV at weeks 4 and 6.
At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and, defined as fulfilling at least two of the following three criteria at week 30, will receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
- Anti-PLA2R levels is ≥ 25% of baseline
- Proteinuria is ≥ 50% of baseline
- Serum albumin is < 2.8 g/dL
After the 52 week treatment period, all participants will be followed on no study medication with assessment of the primary endpoint (CR or PR) at week 104.
The primary endpoint will be assessed at week 104 because the proteinuric response to treatment is known to lag behind the active treatment period and is recommended to be assessed at least 18 months after the initiation of therapy. There will be a tolerance endpoint at week 156 to determine if treatment with belimumab with rituximab results in a more durable remission compared to rituximab alone, and to assess the rate of relapse after having achieved complete or partial remission.
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Being tested
- Belimumab, Placebo for Belimumab, Rituximab
- Keywords
- Primary Membranous Nephropathy, nephrotic syndrome, Pharmacokinetics (PK) Analysis, Double-Blind (Masked), Placebo-Controlled Clinical Trial, Co-administered belimumab and rituximab
- Medical subject headings
- Glomerulonephritis, Membranous, Nephrotic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BelimumabDrug
Also called Benlysta®
Belimumab is a recombinant, human, IgG1λ monoclonal antibody.
Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
Standard Weekly dose:
Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
Placebo for BelimumabDrug
Also called Belimumab placebo
The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
Standard weekly dose:
Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously.
RituximabDrug
Also called Rituxan®
Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages.
Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid.
Dose: 1000 mg intravenously (IV), Week 4 and -6.
| Study group | Role | What they receive |
|---|---|---|
| Part A: Low Proteinuria Group - Belimumab and Rituximab | Experimental | Open-label pharmacokinetics (PK) phase.
Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). Receives: Drug: Belimumab; Drug: Rituximab |
| Part A :High Proteinuria Group - Belimumab and Rituximab | Experimental | Open-label pharmacokinetics (PK) phase.
Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6.
High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). Receives: Drug: Belimumab; Drug: Rituximab |
| Part B: Belimumab and Rituximab | Experimental | Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.
At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
* Anti-PLA2R level is ≥ 25% of baseline
* Proteinuria is ≥ 50% of baseline
* Serum albumin is < 2.8 g/dL Receives: Drug: Belimumab; Drug: Rituximab |
| Part B: Placebo and Rituximab | Placebo comparator | Participants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6.
At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
* Anti-PLA2R level is ≥ 25% of baseline
* Proteinuria is ≥ 50% of baseline
* Serum albumin is < 2.8 g/dL Receives: Drug: Placebo for Belimumab; Drug: Rituximab |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104.
. CR is defined as proteinuria of ≤ 0.3 g/day with a serum albumin ≥ 3.5 g/dL. PR is defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria < 3.5 g/day glomerular filtration rate (eGFR) from baseline.
Measured: Week 104
Secondary outcomes (15)
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 52 and Week 156.
Measured: Week 52, Week 156
Proportion of Participants in Complete Remission (CR) at Week 52, Week 104 and Week 156.
Measured: Week 52, Week 104, Week 156
Proportion of Participants in PR but not CR at Week 52, Week 104, Week 156.
Measured: Week 52, Week 104, Week 156
Time to Relapse for Participants who Achieved CR or PR.
Measured: Up to 156 Weeks (3 Years)
Level of Proteinuria at Week 52, Week 104 and Week 156.
Measured: Week 52, Week 104, Week 156
Proportion of participants meeting criteria for a second course of rituximab at week 30
Measured: Week 30
Proportion of Participants in CR or PR and Anti-PLA2R Negative at week 52, 104, and 156
Measured: Week 52, Week 104, Week 156
Proportion of Participants in PR and Anti-PLA2R Negative at week 52, 104, and 156
Measured: Week 52, Week 104, Week 156
Proportion of participants in PR but not CR and who are anti-PLA2R negative at week 52, 104, and 156
Measured: Week 52, Week104, Week 156
Proportion of Participants who are Anti-PLA2R Negative at week 52, 104, and 156
Measured: Week 52, Week104, Week 156
Quality of life at weeks 52, 104, and 156
Measured: Week 52, Week104, Week 156
Incidence of Adverse Events (AEs).
Measured: Week 0 to Week 52
Incidence of Grade 3 or Higher Infectious Adverse Events (AEs): By Treatment Group
Reference: NCI-CTCAE manual titled, National Cancer Institute (NCI)s Common Terminology Criteria for Adverse Events Version 5.0 (published November 27, 2017).
Measured: Week 0 to Week 52
Incidence of Arterial Thromboembolic Events: By Treatment Group
Peripheral vascular embolism, mesenteric infarct, or myocardial infarction.
Measured: Week 0 to Week 52
Incidence of Venous Thromboembolic Events: By Treatment Group
Venous thromboembolic event (VTE) is defined as a symptomatic deep vein thrombosis (DVT): the formation of a blood clot in a deep vein, detected by systematic compression ultrasonography, symptomatic DVT, or symptomatic fatal or non-fatal pulmonary embolism (PE). An embolism is a clot in the blood that forms and blocks a blood vessel. A pulmonary embolism is a blood clot that has travelled from elsewhere in the body through the blood stream to block the main artery of the lung or one of its branches.
Measured: Week 0 to Week 52
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 May 2019
- Study start6 Mar 2020
- Primary completion1 Mar 2029 (estimated)
- Study completion1 Mar 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Membranous NephropathyStudies of the same condition, open and under way.
- More trials run by National Institute of Allergy and Infectious Diseases (NIAID)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 58 participants (estimated)
Sponsor and investigators
- Sponsor type
- US National Institutes of Health
- Collaborators
- Immune Tolerance Network (ITN), GlaxoSmithKline, PPD Development, LP, Rho Federal Systems Division, Inc.
- Responsible party
- Sponsor
- Investigators
- Patrick Nachman, Study chair, University of Minnesota, Department of Medicine, Division of Renal Diseases and HypertensionIñaki Sanz, Study chair, Emory University, Department of Medicine, Division of Rheumatology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03949855
- Sponsor's protocol ID
- DAIT ITN080AI
- Other IDs
- NIAID CRMS ID#:38478
- Acronym
- REBOOT
- Status last verified
- Sep 2026
- First submitted
- 13 May 2019
- Last updated
- 18 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Publications
Ayoub I, Nachman PH. Advances in ANCA-associated vasculitis and lupus nephritis. Nat Rev Nephrol. 2021 Feb;17(2):89-90. doi: 10.1038/s41581-020-00388-x. No abstract available.
PubMed 33311560
Study at a glance
From the registry record, last updated by the sponsor on 18 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (ITN080AI)
- ClinicalTrials.gov ID
- NCT03949855
- Acronym / sponsor ID
- REBOOT / DAIT ITN080AI
- Conditions
- Membranous Nephropathy, Nephrotic Syndrome
- Keywords
- Primary Membranous Nephropathy, nephrotic syndrome, Pharmacokinetics (PK) Analysis, Double-Blind (Masked), Placebo-Controlled Clinical Trial, Co-administered belimumab and rituximab
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 58 participants (estimated)
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)US National Institutes of Health
- Collaborators
- Immune Tolerance Network (ITN), GlaxoSmithKline, PPD Development, LP, Rho Federal Systems Division, Inc.
- Study start
- 6 Mar 2020 (actual)
- Primary completion
- 1 Mar 2029 (estimated)
- Study completion
- 1 Mar 2030 (estimated)
- First posted
- 14 May 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to evaluate the effectiveness of belimumab and intravenous rituximab co-administration at inducing a complete or partial remission (CR or PR) compared to rituximab alone in participants with primary membranous nephropathy.
Background:
Primary membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults. MN affects individuals of all ages and races. The peak incidence of MN is in the fifth decade of life.
Primary MN is recognized to be an autoimmune disease, a disease where the body's own immune system causes damage to kidneys. This damage can cause the loss of too much protein in the urine.
Drugs used to treat MN aim to reduce the attack by one's own immune system on the kidneys by blocking inflammation and reducing the immune system's function. These drugs can have serious side effects and often do not cure the disease. There is a need for new treatments for MN that are better at improving the disease while reducing fewer treatment associated side effects.
In this study, researchers will evaluate if treatment with a combination of two different drugs, belimumab and rituximab, is effective at blocking the immune attacks on the kidney compared to rituximab alone. Rituximab works by decreasing a type of immune cell, called B cells. B cells are known to have a role in MN. Once these cells are removed, disease may become less active or even inactive. However, after stopping treatment, the body will make new B cells which may cause disease to become active again.
Belimumab works by decreasing the new B cells produced by the body and, may even change the type of new B cells subsequently produced. Belimumab is approved by the US Food and Drug Administration (FDA) to treat systemic lupus erythematosus (also referred to as lupus or SLE). Rituximab is approved by the FDA to treat some types of cancer, rheumatoid arthritis, and vasculitis. Neither rituximab nor belimumab is approved by the FDA to treat MN. Treatment with a combination of belimumab and rituximab has not been studied in individuals with MN, but has been tested in other autoimmune diseases, including lupus nephritis and Sjögren's syndrome.
Detailed description
This trial is a two-part study (Part A and Part B) of adults with primary membranous nephropathy (MN), ages 18-75 inclusive. The study will be conducted at multiple sites in the United States and Canada.
Part A: Open-label Phase
Part A is an open-label, PK study to compare belimumab exposure between participants who have "low" proteinuria (≥ 4 to < 8 g/day) and "high" proteinuria (≥ 8 g/day) at Visit -1.
Initially Part A planned to enroll 20 individuals with primary MN: 10 individuals with low proteinuria and 10 individuals with high proteinuria. All Part A participants received 200 mg subcutaneous belimumab weekly, the initially approved dose of belimumab in SLE, for 52 doses (weeks 0-51). Trough serum belimumab levels would be obtained weekly following the first 4 doses of belimumab. All participants would receive rituximab 1000 mg IV at weeks 4 and 6, and are followed after the 52 week treatment period on no study medication until week 156.
Belimumab trough levels were to be analyzed after all 20 participants received the first 4 doses to compare the belimumab exposure between the low and high proteinuria groups. If the belimumab exposure was not comparable between the high and low proteinuria groups, the belimumab dose would be doubled to 400 mg/weekly for participants with high proteinuria in Part B. Dose determination for participants with high proteinuria in Part B would be made by an adjudication committee comprised of the Protocol Chair, NIAID Medical Monitor, ITN Clinical Trial Physician, and Rho Scientist, in consultation with the belimumab PK expert at GSK.
Due in part to the observed imbalance in enrollment between the high and low proteinuria groups, an ad hoc PK analysis was conducted. The serum belimumab trough levels of the first 12 participants (8 with high proteinuria and 4 with low proteinuria) who received the first 4 belimumab doses were analyzed to compare belimumab exposure between the low and high proteinuria groups.
The results of the PK analysis were reviewed by the adjudication committee, who determined that the results did not support doubling the dose of belimumab in individuals with high proteinuria nor did it identify a new proteinuria threshold that warranted an increased belimumab dose. The belimumab PK expert at GSK concurred. Thus, enrollment into Part A has been suspended, and all participants in Part B are to receive the same dose of belimumab. All participants currently enrolled in Part A continue to receive belimumab and rituximab as previously planned and are undergoing the safety assessments as presented in Appendix A.
All enrolled participants in Part A will be followed until week 156 and will be assessed for the same study endpoints as participants in Part B.
Part B: Randomized Phase
Part B is a prospective, randomized, phase II, double-blind, placebo-controlled, multicenter clinical trial in adults with primary MN to assess the effectiveness of belimumab and rituximab at treating primary MN. Part B is commencing after the completion of the ad hoc PK analysis, which did not support increasing the belimumab dose in participants with high proteinuria.
A total of 58 participants will be randomized into two treatment arms.
Randomization will be stratified by low (≥ 4 to < 8 g/day) and high proteinuria (≥ 8 g/day). Eleven participants who entered Part B prior to protocol version 7.0 were randomized at a 1:1 ratio; 47 participants entering at or after protocol version 7.0 will be randomized at a 3:1 ratio. A total of 41 participants are projected to be enrolled in the belimumab and rituximab arm and 17 participants in the belimumab placebo and rituximab arm. The effectiveness of belimumab with rituximab will be evaluated using a hybrid control arm that combines participants who receive belimumab placebo and rituximab in this study and the subgroup of subjects with primary MN in the MENTOR trial who were anti-PLA2R positive at baseline and received rituximab alone. The randomized arms will also be used to evaluate the safety of adding belimumab to rituximab in primary MN and to support mechanistic studies.
Participants randomized to the belimumab and rituximab arm will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. This dosing regimen is based on the recommended dosing of subcutaneous belimumab for lupus nephritis. Participants randomized to the belimumab placebo and rituximab arm will receive subcutaneous belimumab placebo according to the same dose and schedule.
Participants in both arms will receive rituximab 1000 mg IV at weeks 4 and 6.
At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and, defined as fulfilling at least two of the following three criteria at week 30, will receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36):
- Anti-PLA2R levels is ≥ 25% of baseline
- Proteinuria is ≥ 50% of baseline
- Serum albumin is < 2.8 g/dL
After the 52 week treatment period, all participants will be followed on no study medication with assessment of the primary endpoint (CR or PR) at week 104.
The primary endpoint will be assessed at week 104 because the proteinuric response to treatment is known to lag behind the active treatment period and is recommended to be assessed at least 18 months after the initiation of therapy. There will be a tolerance endpoint at week 156 to determine if treatment with belimumab with rituximab results in a more durable remission compared to rituximab alone, and to assess the rate of relapse after having achieved complete or partial remission.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Part A: Low Proteinuria Group - Belimumab and Rituximab | Experimental | Drug: Belimumab, Drug: RituximabOpen-label pharmacokinetics (PK) phase. Participants with low proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6. Low proteinuria classification: The excretion of ≥4 to <8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). |
| Part A :High Proteinuria Group - Belimumab and Rituximab | Experimental | Drug: Belimumab, Drug: RituximabOpen-label pharmacokinetics (PK) phase. Participants with high proteinuria classification will receive belimumab weekly subcutaneous injections (52 doses administered Week 0 to Week 51) and rituximab infusions at Weeks 4 and 6. High proteinuria classification: The excretion of ≥8 g/day of protein by the kidneys in adults. (Normal in adults: 0.15 g/day). |
| Part B: Belimumab and Rituximab | Experimental | Drug: Belimumab, Drug: RituximabParticipants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6. At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36): * Anti-PLA2R level is ≥ 25% of baseline * Proteinuria is ≥ 50% of baseline * Serum albumin is < 2.8 g/dL |
| Part B: Placebo and Rituximab | Placebo comparator | Drug: Placebo for Belimumab, Drug: RituximabParticipants in the low proteinuria classification stratification, based upon Part A, and randomized to this arm, will receive subcutaneous belimumab placebo 400 mg (two 200 mg injections) once weekly from weeks 0-3, and then 200 mg once weekly from weeks 4-51. Participants will receive rituximab infusions at Weeks 4 and 6. At week 30, participants will be assessed for a response to study treatment. Participants who meet at least two out of the following three criteria at week 30 will be considered to have an inadequate response to study treatment and receive a second course of rituximab (defined as 1000 mg IV given at weeks 34 and 36): * Anti-PLA2R level is ≥ 25% of baseline * Proteinuria is ≥ 50% of baseline * Serum albumin is < 2.8 g/dL |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Subjects must meet all of the following criteria to be eligible for this study-
- Age 18 to 75 years inclusive
- Diagnosis of one of the following:
- Serum anti-PLA2R positive
- eGFR ≥ 30 mL/min/1.73m2 while on maximally tolerated RAS blockade
Key exclusion criteria (39 listed)
- Subjects meeting any of the following criteria will not be eligible for this study-
- Secondary cause of MN (e.g., SLE, drug, infection, malignancy) suggested by review of the patient's medical history and/or clinical presentation
- Rituximab use within the previous 12 months
- Rituximab use > 12 months ago:
- Use of anti-B cell therapy other than rituximab within the previous 12 months (or 5 half-lives, whichever is greater)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BelimumabAlso: Benlysta®Belimumab is a recombinant, human, IgG1λ monoclonal antibody. Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use. Standard Weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously. | Drug | Part A :High Proteinuria Group - Belimumab and Rituximab, Part A: Low Proteinuria Group - Belimumab and Rituximab, Part B: Belimumab and Rituximab |
| Placebo for BelimumabAlso: Belimumab placeboThe placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use. Standard weekly dose: Part A: 200 mg. administered subcutaneously. Part B: 400 mg (two 200 mg injections) from weeks 0-3, and then 200 mg from weeks 4-51, administered subcutaneously. | Drug | Part B: Placebo and Rituximab |
| RituximabAlso: Rituxan®Rituximab is a monoclonal antibody with specificity for CD20, a transmembrane protein expressed on B cells from the pre-B to memory cell development stages. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg/10 mL or 500 mg/50 mL single-use vials for infusion. It is a clear, colorless liquid. Dose: 1000 mg intravenously (IV), Week 4 and -6. | Drug | Part A :High Proteinuria Group - Belimumab and Rituximab, Part A: Low Proteinuria Group - Belimumab and Rituximab, Part B: Belimumab and Rituximab, Part B: Placebo and Rituximab |
Primary outcome
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104.
Time frame: Week 104
. CR is defined as proteinuria of ≤ 0.3 g/day with a serum albumin ≥ 3.5 g/dL. PR is defined as a 50% or greater decrease in proteinuria compared to baseline and proteinuria < 3.5 g/day glomerular filtration rate (eGFR) from baseline.
15 secondary outcomes
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 52 and Week 156.
Time frame: Week 52, Week 156
Proportion of Participants in Complete Remission (CR) at Week 52, Week 104 and Week 156.
Time frame: Week 52, Week 104, Week 156
Proportion of Participants in PR but not CR at Week 52, Week 104, Week 156.
Time frame: Week 52, Week 104, Week 156
Time to Relapse for Participants who Achieved CR or PR.
Time frame: Up to 156 Weeks (3 Years)
Level of Proteinuria at Week 52, Week 104 and Week 156.
Time frame: Week 52, Week 104, Week 156
Proportion of participants meeting criteria for a second course of rituximab at week 30
Time frame: Week 30
Proportion of Participants in CR or PR and Anti-PLA2R Negative at week 52, 104, and 156
Time frame: Week 52, Week 104, Week 156
Proportion of Participants in PR and Anti-PLA2R Negative at week 52, 104, and 156
Time frame: Week 52, Week 104, Week 156
Proportion of participants in PR but not CR and who are anti-PLA2R negative at week 52, 104, and 156
Time frame: Week 52, Week104, Week 156
Proportion of Participants who are Anti-PLA2R Negative at week 52, 104, and 156
Time frame: Week 52, Week104, Week 156
Quality of life at weeks 52, 104, and 156
Time frame: Week 52, Week104, Week 156
Incidence of Adverse Events (AEs).
Time frame: Week 0 to Week 52
Incidence of Grade 3 or Higher Infectious Adverse Events (AEs): By Treatment Group
Time frame: Week 0 to Week 52
Incidence of Arterial Thromboembolic Events: By Treatment Group
Time frame: Week 0 to Week 52
Incidence of Venous Thromboembolic Events: By Treatment Group
Time frame: Week 0 to Week 52
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Sep 2026.
- Derived from this study: PubMed 33311560Ayoub I, Nachman PH. Advances in ANCA-associated vasculitis and lupus nephritis. Nat Rev Nephrol. 2021 Feb;17(2):89-90. doi: 10.1038/s41581-020-00388-x. No abstract available.
- National Institute of Allergy and Infectious Diseases (NIAID)Link provided by the sponsor.
- Division of Allergy, Immunology, and Transplantation (DAIT)Link provided by the sponsor.
- Immune Tolerance Network (ITN)Link provided by the sponsor.
- Visit this ITN Study website for more informationLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
Related trials for Membranous Nephropathy
RecruitingPhase 2
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Focal Segmental Glomerulosclerosis, Minimal Change Disease
RecruitingPhase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Nephrotic Syndrome, Proteinuria
Not yet recruitingObservational study
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
RecruitingObservational study
Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis
Membranous Nephropathy
Active, not recruitingPhase 1/2
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
Lupus Nephritis, Immunoglobulin A Nephropathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
University of Alabama at Birmingham School of Medicine: Division of Nephrology
Birmingham, United States
University of California San Francisco
San Francisco, United States
Patrick Nachman study chair
University of Minnesota, Department of Medicine, Division of Renal Diseases and Hypertension
Iñaki Sanz study chair
Emory University, Department of Medicine, Division of Rheumatology
20 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Belimumab and Rituximab in people with Membranous Nephropathy and Nephrotic Syndrome, run by National Institute of Allergy and Infectious Diseases (NIAID) at 20 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 39 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 20 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of Participants in Complete or Partial Remission (CR or PR) at Week 104. (time frame: Week 104). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03949855, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Sep 2026.